Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 97

1.

[Intestinal fatty acid binding protein: marker of enterocyte damage in acute and chronic gastroenterological diseases].

Kocsis D, Papp M, Tornai T, Tulassay Z, Herszényi L, Tóth M, Juhász M.

Orv Hetil. 2016 Jan 10;157(2):59-64. doi: 10.1556/650.2016.30336. Review. Hungarian.

PMID:
26726140
2.

Prevalence of inflammatory bowel disease among coeliac disease patients in a Hungarian coeliac centre.

Kocsis D, Tóth Z, Csontos ÁA, Miheller P, Pák P, Herszényi L, Tóth M, Tulassay Z, Juhász M.

BMC Gastroenterol. 2015 Oct 19;15:141. doi: 10.1186/s12876-015-0370-7.

3.

[Peptic ulcer disease and stress].

Herszényi L, Juhász M, Mihály E, Tulassay Z.

Orv Hetil. 2015 Aug 30;156(35):1426-9. doi: 10.1556/650.2015.30249. Review. Hungarian.

PMID:
26299834
4.

[Prevention of acute pancreatitis following endoscopic retrograde cholangiopancreatography].

Patai Á, Patai ÁV, Solymosi N, Tulassay Z, Herszényi L.

Orv Hetil. 2015 May 3;156(18):715-9. doi: 10.1556/OH.2015.30143. Review. Hungarian.

PMID:
26042778
5.

TIMP-1: a strong player in colorectal cancer.

Herszényi L.

J Gastrointestin Liver Dis. 2014 Dec;23(4):365-6. doi: 10.15403/jgld.2014.1121.234.tmp1. No abstract available.

6.

Colorectal cancer in patients with inflammatory bowel disease: the true impact of the risk.

Herszényi L, Barabás L, Miheller P, Tulassay Z.

Dig Dis. 2015;33(1):52-7. doi: 10.1159/000368447. Epub 2014 Dec 17. Review.

PMID:
25531497
7.

Impact of proteolytic enzymes in colorectal cancer development and progression.

Herszényi L, Barabás L, Hritz I, István G, Tulassay Z.

World J Gastroenterol. 2014 Oct 7;20(37):13246-57. doi: 10.3748/wjg.v20.i37.13246. Review.

8.

[Statins and gastrointestinal cancers].

Sági V, Herszényi L, Tulassay Z, Gasztonyi B.

Orv Hetil. 2014 May 4;155(18):687-93. doi: 10.1556/OH.2014.29901. Review. Hungarian.

PMID:
24776382
9.

Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.

Dignass A, Stoynov S, Dorofeyev AE, Grigorieva GA, Tomsová E, Altorjay I, Tuculanu D, Bunganič I, Pokrotnieks J, Kupčinskas L, Dilger K, Greinwald R, Mueller R; International Budenofalk Study Group.

J Crohns Colitis. 2014 Sep;8(9):970-80. doi: 10.1016/j.crohns.2014.01.021. Epub 2014 Feb 15.

10.

[Gastritis and gastropathy].

Mihály E, Micsik T, Juhász M, Herszényi L, Tulassay Z.

Orv Hetil. 2014 Jan 12;155(2):43-61. doi: 10.1556/OH.2014.29807. Review. Hungarian.

PMID:
24389321
11.

Letter: dermatological complications with therapy for inflammatory bowel disease.

Mihály E, Székely H, Herszényi L, Wikonkál N, Tulassay Z.

Aliment Pharmacol Ther. 2014 Jan;39(2):232-3. doi: 10.1111/apt.12566. No abstract available.

12.

[Vitamin D level in Hungarian patients with inflammatory bowel diseases].

Lőrinczy K, Lakatos PL, Tóth M, Salamon Á, Nemes A, Csontos ÁA, Fekete B, Terjék O, Herszényi L, Juhász M, Tulassay Z, Miheller P.

Orv Hetil. 2013 Nov 17;154(46):1821-8. doi: 10.1556/OH.2013.29750. Hungarian.

PMID:
24212042
13.

Probiotics in the management of Crohn's disease and ulcerative colitis.

Müllner K, Miheller P, Herszényi L, Tulassay Z.

Curr Pharm Des. 2014;20(28):4556-60. Review.

PMID:
24180407
14.

[Somatostatin and the digestive system. Clinical experiences].

Herszényi L, Mihály E, Tulassay Z.

Orv Hetil. 2013 Sep 29;154(39):1535-40. doi: 10.1556/OH.2013.29721. Review. Hungarian.

PMID:
24058098
15.

Coeliac disease in a 15-year period of observation (1997 and 2011) in a Hungarian referral centre.

Kocsis D, Miheller P, Lőrinczy K, Herszényi L, Tulassay Z, Rácz K, Juhász M.

Eur J Intern Med. 2013 Jul;24(5):461-7. doi: 10.1016/j.ejim.2013.02.015. Epub 2013 Mar 24.

PMID:
23535227
16.

The behavior of matrix metalloproteinases and their inhibitors in colorectal cancer.

Herszényi L, Hritz I, Lakatos G, Varga MZ, Tulassay Z.

Int J Mol Sci. 2012 Oct 16;13(10):13240-63. doi: 10.3390/ijms131013240. Review.

17.
18.

The impact of matrix metalloproteinases and their tissue inhibitors in inflammatory bowel diseases.

Lakatos G, Hritz I, Varga MZ, Juhász M, Miheller P, Cierny G, Tulassay Z, Herszényi L.

Dig Dis. 2012;30(3):289-95. doi: 10.1159/000336995. Epub 2012 Jun 20.

PMID:
22722554
19.

The role of inflammation and proteinases in tumor progression.

Herszényi L, Lakatos G, Hritz I, Varga MZ, Cierny G, Tulassay Z.

Dig Dis. 2012;30(3):249-54. doi: 10.1159/000336914. Epub 2012 Jun 20. Review.

PMID:
22722549
20.

The role of autoantibodies in inflammatory bowel disease.

Herszényi L, Tulassay Z.

Dig Dis. 2012;30(2):201-7. doi: 10.1159/000336702. Epub 2012 Jun 20. Review.

PMID:
22722439

Supplemental Content

Loading ...
Support Center